Elsevier

Cancer Treatment Reviews

Volume 50, November 2016, Pages 48-60
Cancer Treatment Reviews

Tumour Review
Extreme hypofractionation for early prostate cancer: Biology meets technology

https://doi.org/10.1016/j.ctrv.2016.08.005Get rights and content

Highlights

  • An exhaustive review of extreme hypofractionated prostate radiotherapy is presented.

  • Available clinical data encourage hypofractionation in prostate cancer treatment.

  • Several technological improvements address the issue of accuracy in hypofractionation.

  • We present outcome results from 20 clinical studies enrolling more than 40 patients.

Abstract

The aim of this review is to present the available radiobiological, technical and clinical data about extreme hypofractionation in primary prostate cancer radiotherapy. The interest in this technique is based on the favourable radiobiological characteristics of prostate cancer and supported by advantageous logistic aspects deriving from short overall treatment time. The clinical validity of short-term treatment schedule is proven by a body of non-randomised studies, using both isocentric (LINAC-based) or non-isocentric (CyberKnife®-based) stereotactic body irradiation techniques. Twenty clinical studies, each enrolling more than 40 patients for a total of 1874 treated patients, were revised in terms of technological setting, toxicity, outcome and quality of life assessment. The implemented strategies for the tracking of the prostate and the sparing of the rectal wall have been investigated with particular attention. The urinary toxicity after prostate stereotactic body irradiation seems slightly more pronounced as compared to rectal adverse events, and this is more evident for late occurring events, but no worse as respect to conventional fractionation schemes. As far as the rate of severe acute toxicity is concerned, in all the available studies the treatment was globally well tolerated. While awaiting long-term data on efficacy and toxicity, the analysed studies suggest that the outcome profile of this approach, alongside the patient convenience and reduced costs, is promising. Forty-eight ongoing clinical trials are also presented as a preview of the expectation from the near future.

Introduction

Prostate cancer (PC) is the most common male malignancy in the Western countries and the second most frequently diagnosed cancer among males worldwide [1], [2]. Approximately 80% of men with newly diagnosed PC will have organ-confined disease. Evidence-based and scientifically approved conventional treatment options for prostate-confined cancer include radical prostatectomy, external beam radiotherapy (EBRT), brachytherapy (BT) and active surveillance [1], [3]. Since head-to-head comparison of different options is not available, the choice is based on the tumour stage and characteristics, patient general conditions and preferences and the centre expertise [1], [4], [5]. Radiation therapy (RT) is one of the well-established treatment approaches in localized PC [1], [3].

During the last decades, tremendous advances in pre-treatment imaging, treatment-planning, delivery and verification, combined with mature results from moderately hypofractionated randomized controlled trials [6], [7], [8], [9], [10], [11], reassuring on the sensitivity of PC to larger fraction sizes, have implemented the opportunity of using fewer large dose per fraction delivered in a short treatment duration. Beyond the obvious advantages in terms of patient convenience and health economics, the unique radiobiology of PC [12], [13], [14], [15], along with the evidence that dose-escalation yields better outcomes [16], [17], [18], [19], [20], seems to favour this strategy, widely known as stereotactic body radiation therapy (SBRT).

The aim of this article is to summarize the radiobiological, technical and clinical data available in the literature about SBRT in PC patients. According to the Italian Association of Radiation Oncology (AIRO), the current review could serve as a guide for clinical implementation of extreme hypofractionation programs in well-equipped RT facilities with appropriate clinical and physics expertise. Such approach can be considered in strictly selected organ-confined PC [104], [105].

Section snippets

Radiobiological rationale

The linear-quadratic model represents the basis for predicting the clinical effects of alternative fractionation schemes in RT. In this model, the tissue response to altered fractionation (i.e. different from the standard 2 Gy/fraction) is determined by the tissue α/β ratio. A tissue with a high α/β ratio is less sensitive to a high dose per fraction or hypofractionated RT compared to a tissue with a low α/β ratio. In clinical practice, most tumours have a high α/β ratio (about 10 Gy); therefore,

Technical aspects

SBRT consists in delivering few, highly focused fractions of high doses of RT. Initially introduced for the treatment of brain tumours by Leksell et al. [34], it has known a larger diffusion in the treatment of extra-cranial targets in the last 20 years [35]. The adoption of these highly hypofractionated treatments in the therapeutic approach to PC has been possible thanks to a better knowledge of the tumour biology, but also to several technological improvements allowing a precise localization

Planning and dosimetric considerations

Dosimetrically, the large dose, and accordingly the high monitor unit (MU) numbers, for each fraction associated with the intensity-modulated SBRT delivery might often be different from the conventionally fractionated IMRT. Therefore, SBRT delivery implies additional efforts in the treatment planning process, due to the need of keeping more beams and more intensity segments within the machine constraints of delivering (1–2 MU/segment). This optimisation process allows the safe delivery of high

Clinical outcomes

Table 1 summarizes data about the clinical outcomes and the toxicity rates of the analysed studies [47], [69], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89]. In the majority of these trials, low/intermediate-risk PC patients who underwent experimental schedules of fraction sizes ranging between 6.7 and 10 Gy were the target population. The majority of clinical evidence of prostate SBRT comes from trials using the non-coplanar

Ongoing clinical trials and future directions

We searched in https://clinicaltrials.gov/ [101] for specific keywords to identify studies related to extreme hypofractionation in PC. In particular, five researches were performed on the 1st February 2016, including: “Prostate SBRT”, “Prostate focal radiotherapy”, “Prostate hypofractionation”, “Prostate dominant lesion” and “Prostate monotherapy”, thus obtaining 252 results. They were evaluated for adequacy to the scope of this review, selecting non-repeating results and excluding studies

Conclusions

The use of SBRT as primary PC treatment is steadily increasing. In the United States, 8.8% of low-risk patients treated at academic programs in 2012 received SBRT, with respect to <1% of patients treated with SBRT in 2004 across all risk groups [103]. Several prospective and retrospective trials of extreme hypofractionation have already been published, although only three randomized studies comparing prostate SBRT with a standard of care are currently ongoing. Thereby, no definitive conclusions

Author contributions

All authors actively contributed to the review of the literature, analysis of relevant studies and preparation of the manuscript. All authors read and approved the final version before submission. Barbara A. Jereczek-Fossa served as scientific supervisor.

Conflict of interest

None to be declared.

Acknowledgment

This study was partially supported by AIRC – Associazione Italiana per la Ricerca sul Cancro (IG-13218).

References (105)

  • D.A. Kuban et al.

    Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer

    Int J Radiat Oncol Biol Phys

    (2008)
  • D.P. Dearnaley et al.

    Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomized controlled trial

    Lancet Oncol

    (2014)
  • D.J. Brenner et al.

    Fractionation and protraction for radiotherapy of prostate carcinoma

    Int J Radiat Oncol Biol Phys

    (1999)
  • A.C. Tree et al.

    Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?

    Clin Oncol (R Coll Radiol)

    (2014)
  • S. Clemente et al.

    Role of the technical aspects of hypofractionated radiation therapy treatment of prostate cancer: a review

    Int J Radiat Oncol Biol Phys

    (2015)
  • B.F. Koontz et al.

    A systematic review of hypofractionation for primary management of prostate cancer

    Eur Urol

    (2015)
  • A.E. Nahum

    The radiobiology of hypofractionation

    Clin Oncol (R Coll Radiol)

    (2015)
  • I.R. Vogelius et al.

    Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?

    Int J Radiat Oncol Biol Phys

    (2013)
  • D.R. Henderson et al.

    Stereotactic body radiotherapy for prostate cancer

    Clin Oncol (R Coll Radiol)

    (2015)
  • C.E. Round et al.

    Radiotherapy demand and activity in England 2006–2020

    Clin Oncol (R Coll Radiol)

    (2013)
  • C.D. Collins et al.

    Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique

    Clin Oncol (R Coll Radiol)

    (1991)
  • B. De Bari et al.

    Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature

    Crit Rev Oncol Hematol

    (2015)
  • Z.S. Fawaz et al.

    Fiducial marker implantation in prostate radiation therapy: complication rates and technique

    Cancer Radiother

    (2014)
  • J.F. Langenhuijsen et al.

    Ultrasound-guided transrectal implantation of gold markers for prostate localization during external beam radiotherapy: complication rate and risk factors

    Int J Radiat Oncol Biol Phys

    (2007)
  • M.R. Moman et al.

    Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life

    Radiother Oncol

    (2010)
  • C. Udrescu et al.

    Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images

    Cancer Radiother

    (2013)
  • G. Mok et al.

    Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review

    Int J Radiat Oncol Biol Phys

    (2014)
  • A. Loblaw et al.

    Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes

    Radiother Oncol

    (2013)
  • P.J. Prada et al.

    Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients

    Brachytherapy

    (2009)
  • R.B. Wilder et al.

    Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer

    Int J Radiat Oncol Biol Phys

    (2010)
  • W.R. Noyes et al.

    Human collagen injections to reduce rectal dose during radiotherapy

    Int J Radiat Oncol Biol Phys

    (2012)
  • N. Mariados et al.

    Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing IG-IMRT

    Int J Radiat Oncol Biol Phys

    (2015)
  • S. Both et al.

    Real-time study of prostate intrafraction motion during external beam radiotherapy with daily endorectal balloon

    Int J Radiat Oncol Biol Phys

    (2011)
  • A.V. D’Amico et al.

    A practical method to achieve prostate gland immobilization and target verification for daily treatment

    Int J Radiat Oncol Biol Phys

    (2001)
  • E.N. Van Lin et al.

    The effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: a comparative study

    Int J Radiat Oncol Biol Phys

    (2005)
  • L.E. Court et al.

    Motion and shape change when using an endorectal balloon during prostate radiation therapy

    Radiother Oncol

    (2006)
  • C.W. Wang et al.

    Set-up errors due to endorectal balloon positioning in intensity modulated radiation therapy for prostate cancer

    Radiother Oncol

    (2007)
  • R.J. Smeenk et al.

    Is there a role for endorectal balloons in prostate radiotherapy? A systematic review

    Radiother Oncol

    (2010)
  • S. Ahmad et al.

    Impact of setup uncertainty in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with Peacock/IMRT

    Med Dosim

    (2005)
  • M.T. Vlachaki et al.

    Impact of endorectal balloon in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with IMRT

    Med Dosim

    (2007)
  • R.R. Patel et al.

    Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer

    Radiother Oncol

    (2003)
  • M.V. Sanghani et al.

    Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy

    Urol Oncol

    (2004)
  • E.N. Van Lin et al.

    Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy

    Int J Radiat Oncol Biol Phys

    (2007)
  • G. Goldner et al.

    Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients

    Int J Radiat Oncol Biol Phys

    (2007)
  • R. Woel et al.

    Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization

    Int J Radiat Oncol Biol Phys

    (2005)
  • A.V. D’Amico et al.

    A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization

    Urology

    (2006)
  • J.D. Slater et al.

    Proton therapy for prostate cancer: the initial Loma Linda University experience

    Int J Radiat Oncol Biol Phys

    (2004)
  • S. Hossain et al.

    Dose gradient near target-normal structure interface for nonisocentric cyberknife and isocentric intensity-modulated body RT for prostate cancer

    Int J Radiat Oncol Biol Phys

    (2010)
  • D.B. Fuller et al.

    Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations

    Int J Radiat Oncol Biol Phys

    (2008)
  • C.R. King et al.

    Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer

    Int J Radiat Oncol Biol Phys

    (2012)
  • Cited by (0)

    View full text